| Metric | Value (₹ Cr) | Q3 FY26 | Q4 FY25 |
|---|---|---|---|
| Revenue | 36.81 | 28.0% | 210.4% |
| Total Income | 59.00 | 53.1% | 179.5% |
| Expenditure | 46.31 | 32.2% | 154.3% |
| PBT | 12.69 | 260.5% | 337.6% |
| Net Profit | 8.48 | 220.0% | 319.8% |
| OPM | -9.45% | 6.22pp | 13.57pp |
| NPM | 14.37% | 7.49pp | 4.80pp |
| EPS | 1.84 | 7.1% | 371.8% |
Senores Pharma FY26 Revenue Up 65% to ₹664 Cr
14 May 2026 · 14 May, 2:33 pm
Summary
Senores Pharmaceuticals Limited announced strong audited financial results for Q4 and the full year ended March 31, 2026. The company reported a consolidated total income of ₹190 crore for Q4FY26, up 66% year-on-year, and ₹664 crore for FY26, a 65% increase. Profit After Tax for FY26 surged by 108% to ₹122 crore, driven by robust operational performance, with EBITDA growing by 114% to ₹200 crore. Management highlighted significant growth across all segments, substantial expansion of the ANDA portfolio, and strategic acquisitions and joint ventures aimed at enhancing market access and future growth.
Key Highlights
- 1
Senores Pharmaceuticals reported a significant increase in consolidated total income for Q4FY26, growing by 66% year-on-year to ₹190 crore.
- 2
For the full financial year 2026, consolidated total income surged by 65% year-on-year to ₹664 crore.
- 3
Profit After Tax (PAT) for FY26 demonstrated robust profitability, increasing by 108% year-on-year to ₹122 crore.
- 4
EBITDA for FY26 showed strong operational performance, rising by 114% year-on-year to ₹200 crore.
- 5
The company significantly expanded its product pipeline for Regulated Markets, with approved ANDAs more than doubling from 26 in March 2025 to 51 by March 2026.
- 6
Strategic corporate actions included the acquisition of a 51% membership interest in Zoraya Pharmaceuticals, LLC, USA, and the completion of Phase 1 (75% stake) in the acquisition of Apnar Pharmaceuticals.
- 7
Senores Pharmaceuticals entered the U.S. Federal Market through a 70% joint venture, Amerisyn, creating a direct pathway to supply pharmaceuticals to federal, veterans, and defense sectors.
Management Comments
Swapnil Shah
We have delivered a robust performance across segments in FY26, driven by operational discipline, consistent execution, and strong momentum in key growth areas despite an uncertain operating environment. In the Regulated Markets, our approved ANDA portfolio has more than doubled during the year, increasing from 26 ANDAs as of March 2025 to 51 ANDAs as of March 2026, reflecting the scale and pace of our execution. Out of these, 30 approved ANDAs are yet to be commercialized. Additionally, we have 27 more molecules, involving 65+ unique strengths, at different stages of development. This gives us a strong pipeline of products which are expected to be rolled out over the coming years. We have expanded our manufacturing footprint and product portfolio through acquisition of Apnar Pharmaceuticals. The acquisition enhances scalability, deepens access to Regulated Markets, enables accelerated product launches, improves operating leverage, margins, and expands CDMO-CMO opportunities, positioning Senores for sustained growth. We have commenced product rollouts from the Apnar facility, with initial revenues starting in Q4FY26. While contributions are currently modest, we
Informational and educational content only. Not investment advice.